Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors - Concepedia

Concepedia

Publication | Open Access

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

DOI Full Paper Access

189

Citations

25

References

2014

Year

L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen, Adriane M Zernhelt, Daniel M. Sullivan, Philippe A. Cassier, Eric X. Chen, Andrea Biondo, Ernestina Tetteh, Lillian L. Siu,

Journal of Hematology & Oncology

Abstract

MK-2206 plus carboplatin and paclitaxel, docetaxel, or erlotinib was well-tolerated, with early evidence of antitumor activity.

References

	Year	Citations

Page 1